
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health demonstrates a robust market position, with Simparica Trio leading the market with over 50% share, and Credelio Quattro projected to increase its market share to 16.8% by 2026, indicating positive growth potential in its product offerings. Additionally, the Advantage Family and Seresto products have shown impressive year-over-year growth of 33% and 28%, respectively, in the third quarter of 2025, reinforcing the company’s strong sales momentum. These indications of market leadership and consistent product performance contribute to a favorable outlook for Elanco Animal Health's stock.
Bears say
Elanco Animal Health faces potential refinancing risks that could adversely impact earnings growth in 2026, particularly in light of comparable companies pricing high-yield offerings, such as Dentsply Sirona’s recent $550 million issuance at 8.375%. Additionally, while Elanco's revenue has increased by approximately 50%, the EBITDA margin has decreased by a couple of hundred basis points, indicating challenges in maintaining profitability amidst rising sales. Although the company reported a $28 million EBITDA outperformance in the second quarter, the broader trend of margin compression raises concerns about sustainable financial health.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares